Table of Contents Author Guidelines Submit a Manuscript
Journal of Toxicology
Volume 2012, Article ID 802893, 12 pages
http://dx.doi.org/10.1155/2012/802893
Review Article

Therapeutic Use of Botulinum Toxin in Neurorehabilitation

Neuro-Rehabilitation Unit, Scientific Institute, Hospital IRCSS “Casa Sollievo della Sofferenza”, Viale dei Cappuccini 1, 71013 San Giovanni Rotondo (Foggia), Italy

Received 5 April 2011; Revised 28 June 2011; Accepted 13 July 2011

Academic Editor: S. Ashraf Ahmed

Copyright © 2012 Domenico Intiso. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. R. das Gupta, “Structures of botulinum neurotoxin. Its functional domains and perspectives on the crystalline tipe A toxin,” in Therapy with Botulinum Toxin, J. Jankovic and M. Hallet, Eds., pp. 15–39, Marcel Dekker, New York, NY, USA, 1994. View at Google Scholar
  2. G. Schiavo, F. Benfenati, B. Poulain et al., “Tetanus and botulinum—B neurotoxins block neurotransmitter release by proteolytic cleavage of synapto-brevin,” Nature, vol. 359, no. 6398, pp. 832–835, 1992. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. Tilton, J. Vargus-Adams, and M. R. Delgado, “Pharmacologic treatment of spasticity in children,” Seminars in Pediatric Neurology, vol. 17, no. 4, pp. 261–267, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. E. Keller, “Recovery from botulinum neurotoxin poisoning in vivo,” Neuroscience, vol. 139, no. 2, pp. 629–637, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. C. L. Comella, J. Jankovic, K. M. Shannon et al., “Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia,” Neurology, vol. 65, no. 9, pp. 1423–1429, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. Guidubaldi, A. Fasano, T. Ialongo et al., “Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease,” Movement Disorders, vol. 26, no. 2, pp. 313–319, 2011. View at Publisher · View at Google Scholar · View at PubMed
  7. A. E. Elia, G. Filippini, D. Calandrella, and A. Albanese, “Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review,” Movement Disorders, vol. 24, no. 6, pp. 801–812, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. D. Dressler and R. Eleopra, “Clinical use of non-a botulinum toxins: Botulinum toxin type B,” Neurotoxicity Research, vol. 9, no. 2-3, pp. 121–125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Lagalla, M. Millevolte, M. Capecci, L. Provinciali, and M. G. Ceravolo, “Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling,” Journal of Neurology, vol. 256, no. 4, pp. 563–567, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. Basciani, F. di Rienzo, A. Fontana, M. Copetti, F. Pellegrini, and D. Intiso, “Botulinum toxin type B for sialorrhea in children with cerebral palsy: a randomized trial comparing three doses,” Developmental Medicine & Child Neurology, vol. 53, no. 6, pp. 559–564, 2011. View at Google Scholar
  11. J. W. Lance, “Symposium synopsis,” in Spasticity: Disordered Motor Control, R. G. Feldman, R. R. Young, and W. P. Koella, Eds., pp. 485–494, Yearbook Medical, Chicago, Ill, USA, 1980. View at Google Scholar
  12. G. D. Caty, C. Detrembleur, C. Bleyenheuft, T. Deltombe, and T. M. Lejeune, “Effect of upper limb botulinum toxin injections on impairment, activity, participation, and quality of life among stroke patients,” Stroke, vol. 40, no. 7, pp. 2589–2591, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. A. Esquenazi, “Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity,” European Journal of Neurology, vol. 13, no. 4, supplement 4, pp. 27–34, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. H. Woldag and H. Hummelsheim, “Is the reduction of spasticity by botulinum toxin A beneficial for the recovery of motor function of arm and hand in stroke patients?” European Neurology, vol. 50, no. 3, pp. 165–171, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. G. Sheean, “Botulinum toxin should be first-line treatment for poststroke spasticity,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 4, p. 359, 2009. View at Google Scholar
  16. M. P. Barnes, D. Best, L. Kidd et al., “The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A—initial experiences,” European Journal of Neurology, vol. 12, no. 12, pp. 947–955, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. Brashear, A. L. McAfee, E. R. Kuhn, and J. Fyffe, “Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial,” Archives of Physical Medicine and Rehabilitation, vol. 85, no. 5, pp. 705–709, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. R. Delgado, D. Hirtz, M. Aisen et al., “Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,” Neurology, vol. 74, no. 4, pp. 336–343, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. D. K. Sommerfeld, E. U. B. Eek, A. K. Svensson, L. W. Holmqvist, and M. H. von Arbin, “Spasticity after Stroke: its occurrence and association with motor impairments and activity limitations,” Stroke, vol. 35, no. 1, pp. 134–139, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. E. Lundstrom, A. Terent, and J. Borg, “Prevalence of disabling spasticity 1 year after first-ever stroke,” European Journal of Neurology, vol. 15, no. 6, pp. 533–539, 2008. View at Publisher · View at Google Scholar · View at PubMed
  21. P. P. Urban, T. Wolf, M. Uebele et al., “Occurence and clinical predictors of spasticity after ischemic stroke,” Stroke, vol. 41, no. 9, pp. 2016–2020, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. R. Kaji, Y. Osako, K. Suyama, T. Maeda, Y. Uechi, and M. Iwasaki, “Botulinum toxin type A in post-stroke upper limb spasticity,” Current Medical Research and Opinion, vol. 26, no. 8, pp. 1983–1992, 2010. View at Publisher · View at Google Scholar · View at PubMed
  23. D. M. Simpson, A. Blitzer, A. Brashear et al., “Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology,” Neurology, vol. 70, no. 19, pp. 1699–1706, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. L. Rosales and A. S. Chua-Yap, “Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity,” Journal of Neural Transmission, vol. 115, no. 4, pp. 617–623, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. E. P. Elovic, A. Brashear, D. Kaelin et al., “Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated With focal upper-limb poststroke spasticity for caregivers and patients,” Archives of Physical Medicine and Rehabilitation, vol. 89, no. 5, pp. 799–806, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. P. McCrory, L. Turner-Stokes, I. J. Baguley et al., “Botulinum toxin a for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes,” Journal of Rehabilitation Medicine, vol. 41, no. 7, pp. 536–544, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. F. Gordon, A. Brashear, E. Elovic et al., “Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke,” Neurology, vol. 63, no. 10, pp. 1971–1973, 2004. View at Google Scholar
  28. R. Kaji, Y. Osako, K. Suyama, T. Maeda, Y. Uechi, and M. Iwasaki, “Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial,” Journal of Neurology, vol. 257, no. 8, pp. 1330–1337, 2010. View at Publisher · View at Google Scholar · View at PubMed
  29. S. J. Pittock, A. P. Moore, O. Hardiman et al., “A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke,” Cerebrovascular Diseases, vol. 15, no. 4, pp. 289–300, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. C. Bleyenheuft, S. Cockx, G. Caty, G. Stoquart, T. Lejeune, and C. Detrembleur, “The effect of botulinum toxin injections on gait control in spastic stroke patients presenting with a stiff-knee gait,” Gait and Posture, vol. 30, no. 2, pp. 168–172, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. G. D. Caty, C. Detrembleur, C. Bleyenheuft, and T. M. Lejeune, “Reliability of lower limb kinematics, mechanics and energetics during gait in patients after stroke,” Journal of Rehabilitation Medicine, vol. 41, no. 7, pp. 588–590, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. S. Ozcakir and K. Sivrioglu, “Botulinum toxin in poststroke spasticity,” Clinical Medicine and Research, vol. 5, no. 2, pp. 132–138, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. J. Wissel, A. B. Ward, P. Erztgaard et al., “European consensus table on the use of botulinum toxin type a in adult spasticity,” Journal of Rehabilitation Medicine, vol. 41, no. 1, pp. 13–25, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. S. J. Smith, E. Ellis, S. White, and A. P. Moore, “A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury,” Clinical Rehabilitation, vol. 14, no. 1, pp. 5–13, 2000. View at Google Scholar · View at Scopus
  35. S. A. Yablon, M. F. Brin, A. M. Vandenburgh et al., “Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis,” Movement Disorders, vol. 26, no. 2, pp. 209–215, 2011. View at Publisher · View at Google Scholar · View at PubMed
  36. A. Brashear, M. F. Gordon, E. Elovic et al., “Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke,” New England Journal of Medicine, vol. 347, no. 6, pp. 395–400, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. H. P. Francis, D. T. Wade, L. Turner-Stokes, R. S. Kingswell, C. S. Dott, and E. A. Coxon, “Does reducing spasticity translate into functional benefit? An exploratory meta-analysis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 11, pp. 1547–1551, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. G. Sheean, N. A. Lannin, L. Turner-Stokes, B. Rawicki, and B. J. Snow, “Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement,” European Journal of Neurology, vol. 17, supplement 2, pp. 74–93, 2010. View at Publisher · View at Google Scholar · View at PubMed
  39. J. V. G. Robertson, D. Pradon, D. Bensmail, C. Fermanian, B. Bussel, and N. Roche, “Relevance of botulinum toxin injection and nerve block of rectus femoris to kinematic and functional parameters of stiff knee gait in hemiplegic adults,” Gait and Posture, vol. 29, no. 1, pp. 108–112, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. A. M. O. Bakheit, S. Pittock, A. P. Moore et al., “A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke,” European Journal of Neurology, vol. 8, no. 6, pp. 559–565, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. M. K. Childers, A. Brashear, P. Jozefczyk et al., “Dose-dependent response to intramuscular botulinum toxin type a for upper-limb spasticity in patients after a stroke,” Archives of Physical Medicine and Rehabilitation, vol. 85, no. 7, pp. 1063–1069, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Shaw, H. Rodgers, C. Price et al., “BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A,” Health Technology Assessment, vol. 14, no. 26, pp. 1–113, 2010. View at Google Scholar · View at Scopus
  43. L. Turner-Stokes, I. J. Baguley, S. De Graaff et al., “Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial,” Journal of Rehabilitation Medicine, vol. 42, no. 1, pp. 81–89, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. D. Bensmail, J. V. G. Robertson, C. Fermanian, and A. Roby-Brami, “Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements,” Neurorehabilitation and Neural Repair, vol. 24, no. 3, pp. 273–281, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. E. A. Fridman, M. Crespo, S. G. Argüello et al., “Kinematic improvement following Botulinum Toxin-A injection in upper-limb spasticity due to stroke,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 4, pp. 423–427, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. L. Ada, C. Canning, and T. Dwyer, “Effect of muscle length on strength and dexterity after stroke,” Clinical Rehabilitation, vol. 14, no. 1, pp. 55–61, 2000. View at Google Scholar · View at Scopus
  47. I. Lindgren, A. C. Jonsson, B. Norrving, and A. Lindgren, “Shoulder pain after stroke: a prospective population-based study,” Stroke, vol. 38, no. 2, pp. 343–348, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. J. Y. Lim, J. H. Koh, and N. J. Paik, “Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide,” Stroke, vol. 39, no. 1, pp. 126–131, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. I. Krägeloh-Mann and C. Cans, “Cerebral palsy update,” Brain and Development, vol. 31, no. 7, pp. 537–544, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. L. A. Koman, J. F. Mooney, B. Smith, A. Goodman, and T. Mulvaney, “Management of cerebral palsy with botulinum-A toxin: preliminary investigation,” Journal of Pediatric Orthopaedics, vol. 13, no. 4, pp. 489–495, 1993. View at Google Scholar · View at Scopus
  51. M. B. Lukban, R. L. Rosales, and D. Dressler, “Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence,” Journal of Neural Transmission, vol. 116, no. 3, pp. 319–331, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. C. A. Olesch, S. Greaves, C. Imms, S. M. Reid, and H. K. Graham, “Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: a randomized controlled trial,” Developmental Medicine and Child Neurology, vol. 52, no. 1, pp. 79–86, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. K. Tedroff, F. Granath, H. Forssberg, and Y. Haglund-Akerlind, “Long-term effects of botulinum toxin A in children with cerebral palsy,” Developmental Medicine and Child Neurology, vol. 51, no. 2, pp. 120–127, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. U. Ryll, C. Bastiaenen, R. de Bie, and B. Staal, “Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a systematic review,” Developmental Medicine and Child Neurology, vol. 53, no. 3, pp. 210–216, 2011. View at Publisher · View at Google Scholar · View at PubMed
  55. G. Maanum, R. Jahnsen, J. K. Stanghelle, L. Sandvik, and A. Keller, “Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double-blind placebo controlled-trial,” Journal of Rehabilitation Medicine, vol. 43, no. 4, pp. 338–347, 2011. View at Google Scholar
  56. B. J. Hoare, M. A. Wallen, C. Imms, E. Villanueva, H. B. Rawicki, and L. Carey, “Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE),” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003469, 2010. View at Google Scholar
  57. K. Kim, H. I. Shin, B. S. Kwon, S. J. Kim, I. Y. Jung, and M. S. Bang, “Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial,” Developmental Medicine and Child Neurology, vol. 53, no. 3, pp. 239–244, 2011. View at Publisher · View at Google Scholar · View at PubMed
  58. M. E. Gormley, D. Gaebler-Spira, and M. R. Delgado, “Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review,” Journal of Child Neurology, vol. 16, no. 2, pp. 113–118, 2001. View at Google Scholar · View at Scopus
  59. L. J. Carr, A. P. Cosgrove, P. Gringras, and B. G. R. Neville, “Position paper on the use of botulinum toxin in cerebral palsy,” Archives of Disease in Childhood, vol. 79, no. 3, pp. 271–273, 1998. View at Google Scholar · View at Scopus
  60. P. J. Flett, “Rehabilitation of spasticity and related problems in childhood cerebral palsy,” Journal of Paediatrics and Child Health, vol. 39, no. 1, pp. 6–14, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. E. M. Goldstein, “Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity,” Journal of Child Neurology, vol. 21, no. 3, pp. 189–192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Baker, M. Jasinski, I. Maciag-Tymecka et al., “Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study,” Developmental Medicine and Child Neurology, vol. 44, no. 10, pp. 666–675, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Unlu, A. Cevikol, B. Bal, E. Gonen, O. Celik, and G. Kose, “Multilevel botulinum toxin type a as a treatment for spasticity in children with cerebral palsy: a retrospective study,” Clinics, vol. 65, no. 6, pp. 613–619, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. V. A. Scholtes, A. J. Dallmeijer, D. L. Knol et al., “Effect of multilevel botulinum toxin A and comprehensive rehabilitation on gait in cerebral palsy,” Pediatric Neurology, vol. 36, no. 1, pp. 30–39, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. D. Steenbeek, A. Meester-Delver, J. G. Becher, and G. J. Lankhorst, “The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling,” Clinical Rehabilitation, vol. 19, no. 3, pp. 274–282, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. V. A. Scholtes, A. J. Dallmeijer, D. L. Knol et al., “The combined effect of lower-limb multilevel botulinum toxin type A and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial,” Archives of Physical Medicine and Rehabilitation, vol. 87, no. 12, pp. 1551–1558, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. D. Verplancke, S. Snape, C. F. Salisbury, P. W. Jones, and A. B. Ward, “A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury,” Clinical Rehabilitation, vol. 19, no. 2, pp. 117–125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. U. Bergfeldt, K. Borg, K. Kullander, and P. Julin, “Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients,” Journal of Rehabilitation Medicine, vol. 38, no. 3, pp. 166–171, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. G. Pavesi, R. Brianti, D. Medici, P. Mammi, A. Mazzucchi, and D. Mancia, “Botulinum toxin type A in the treatment of upper limb spasticity among patients with traumatic brain injury,” Journal of Neurology Neurosurgery and Psychiatry, vol. 64, no. 3, pp. 419–420, 1998. View at Google Scholar · View at Scopus
  70. J. Fock, M. P. Galea, B. C. Stillman, B. Rawicki, and M. Clark, “Functional outcome following Botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury,” Brain Injury, vol. 18, no. 1, pp. 57–63, 2004. View at Google Scholar · View at Scopus
  71. E. Guettard, E. Roze, G. Abada et al., “Management of spasticity and dystonia in children with acquired brain injury with rehabilitation and botulinum toxin A,” Developmental Neurorehabilitation, vol. 12, no. 3, pp. 128–138, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. J. van Rhijn, G. Molenaers, and B. Ceulemans, “Botulinum toxin type A in the treatment of children and adolescents with an acquired brain injury,” Brain Injury, vol. 19, no. 5, pp. 331–335, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Hesse, F. Reiter, M. Konrad, and M. T. Jahnke, “Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial,” Clinical Rehabilitation, vol. 12, no. 5, pp. 381–388, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. C. A. Johnson, D. E. Wood, I. D. Swain, A. M. Tromans, P. Strike, and J. H. Burridge, “A pilot study to investigate the combined use of botulinum neurotoxin type A and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke,” Artificial Organs, vol. 26, no. 3, pp. 263–266, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. S. J. Page, E. Elovic, P. Levine, and S. A. Sisto, “Modified constraint-induced therapy and botulinum toxin A: a promising combination,” American Journal of Physical Medicine and Rehabilitation, vol. 82, no. 1, pp. 76–80, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. R. N. Russo, M. Crotty, M. D. Miller, S. Murchland, P. Flett, and E. Haan, “Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial,” Pediatrics, vol. 119, no. 5, pp. 1149–1158, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. I. S. Corry, A. P. Cosgrove, C. M. Duffy et al., “Botulinum toxin A as an alternative to serial casting in the conservative management of equinus in cerebral palsy,” Developmental Medicine and Child Neurology, vol. 37, pp. 20–21, 1995. View at Google Scholar
  78. I. S. Corry, A. P. Cosgrove, C. M. Duffy, S. McNeill, T. C. Taylor, and H. K. Graham, “Botulinum toxin a compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial,” Journal of Pediatric Orthopaedics, vol. 18, no. 3, pp. 304–311, 1998. View at Publisher · View at Google Scholar · View at Scopus
  79. P. J. Flett, L. M. Stern, H. Waddy, T. M. Connell, J. D. Seeger, and S. K. Gibson, “Botulinum toxin a versus fixed cast stretching for dynamic calf tightness in cerebral palsy,” Journal of Paediatrics and Child Health, vol. 35, no. 1, pp. 71–77, 1999. View at Publisher · View at Google Scholar · View at Scopus
  80. R. M. Kay, S. A. Rethlefsen, A. Fern-Buneo, T. A. L. Wren, and D. L. Skaggs, “Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy,” Journal of Bone and Joint Surgery. Series A, vol. 86, no. 11, pp. 2377–2384, 2004. View at Google Scholar · View at Scopus
  81. A. M. Blackmore, E. Boettcher-Hunt, M. Jordan, and M. D. Y. Chan, “A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPDM,” Developmental Medicine and Child Neurology, vol. 49, no. 10, pp. 781–790, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. E. Yaşar, F. Tok, I. Safaz, B. Balaban, B. Yilmaz, and R. Alaca, “The efficacy of serial casting after botulinum toxin type A injection in improving equinovarus deformity in patients with chronic stroke,” Brain Injury, vol. 24, no. 5, pp. 736–739, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. J. M. Lai, G. E. Francisco, and F. B. Willis, “Dynamic splinting after treatment with botulinum toxin type-A: a randomized controlled pilot study,” Advances in Therapy, vol. 26, no. 2, pp. 241–248, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. L. G. Cohen and M. Hallett, “Hand cramps: clinical features and electromyographic patterns in a focal dystonia,” Neurology, vol. 38, no. 7, pp. 1005–1012, 1988. View at Google Scholar · View at Scopus
  85. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group, “A prevalence study of primary dystonia in eight European countries,” Journal of Neurology, vol. 247, no. 10, pp. 787–792, 2000. View at Publisher · View at Google Scholar
  86. A. G. Butler, P. O. Duffey, M. R. Hawthorne, and M. P. Barnes, “An epidemiologic survey of dystonia within the entire population of northeast England over the past nine years,” Advances in Neurology, vol. 94, pp. 95–99, 2004. View at Google Scholar · View at Scopus
  87. E. Altenmüller and H. C. Jabusch, “Focal dystonia in musicians: phenomenology, pathophysiology, triggering factors, and treatment,” Medical Problems of Performing Artists, vol. 25, no. 1, pp. 3–9, 2010. View at Google Scholar · View at Scopus
  88. B. I. Karp, R. A. Cole, L. G. Cohen, S. Grill, J. S. Lou, and M. Hallett, “Long-term botulinum toxin treatment of focal hand dystonia,” Neurology, vol. 44, no. 1, pp. 70–76, 1994. View at Google Scholar · View at Scopus
  89. R. Cole, M. Hallett, and L. G. Cohen, “Double-blind trial of botulinum toxin for treatment of focal hand dystonia,” Movement Disorders, vol. 10, no. 4, pp. 466–471, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. S. Schuele, H. C. Jabusch, R. J. Lederman, and E. Altenmüller, “Botulinum toxin injections in the treatment of musician's dystonia,” Neurology, vol. 64, no. 2, pp. 341–343, 2005. View at Google Scholar · View at Scopus
  91. C. P. Das, D. Dressler, and M. Hallett, “Botulinum toxin therapy of writer's cramp,” European Journal of Neurology, vol. 13, no. 1, supplement 1, pp. 55–59, 2006. View at Publisher · View at Google Scholar · View at PubMed
  92. R. A. Cole, L. G. Cohen, and M. Hallett, “Treatment of musician’s cramp with botulinum toxin,” Medical Problems of Performing Artists, vol. 6, pp. 137–143, 1991. View at Google Scholar
  93. C. Lungu, B. I. Karp, K. Alter, R. Zolbrod, and M. Hallett, “Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more,” Movement Disorders, vol. 26, no. 4, pp. 750–753, 2011. View at Publisher · View at Google Scholar · View at PubMed
  94. M. Hallett, R. Benecke, A. Blitzer, and C. L. Comella, “Treatment of focal dystonias with botulinum neurotoxin,” Toxicon, vol. 54, no. 5, pp. 628–633, 2009. View at Publisher · View at Google Scholar · View at PubMed
  95. B. I. Karp, “Botulinum toxin treatment of occupational and focal hand dystonia,” Movement Disorders, vol. 19, no. 8, supplement 8, pp. S116–S119, 2004. View at Publisher · View at Google Scholar · View at PubMed
  96. S. L. Foad, C. T. Mehlman, and J. Ying, “The epidemiology of neonatal brachial plexus palsy in the United States,” Journal of Bone and Joint Surgery. Series A, vol. 90, no. 6, pp. 1258–1264, 2008. View at Publisher · View at Google Scholar · View at PubMed
  97. B. Backe, E. B. Magnussen, O. J. Johansen, G. Sellaeg, and H. Russwurm, “Obstetric brachial plexus palsy: a birth injury not explained by the known risk factors,” Acta Obstetricia et Gynecologica Scandinavica, vol. 87, no. 10, pp. 1027–1032, 2008. View at Publisher · View at Google Scholar · View at PubMed
  98. A. F. Hoeksma, H. Wolf, and S. L. Oei, “Obstetrical brachial plexus injuries: incidence, natural course and shoulder contracture,” Clinical Rehabilitation, vol. 14, no. 5, pp. 523–526, 2000. View at Google Scholar
  99. M. T. Desiato and B. Risina, “The role of botulinum toxin in the neuro-rehabilitation of young patients with brachial plexus birth palsy,” Pediatric Rehabilitation, vol. 4, no. 1, pp. 29–36, 2001. View at Publisher · View at Google Scholar
  100. R. Hierner, J. D. Rollnik, A. C. Berger, and R. Dengler, “Botulinum toxin type a for the treatment of biceps/triceps co-contraction in obstetrical brachial plexus lesions—preliminary results after a follow-up of 18 months,” European Journal of Plastic Surgery, vol. 24, no. 1, pp. 2–6, 2001. View at Publisher · View at Google Scholar
  101. M. Basciani and D. Intiso, “Botulinum toxin type-A and plaster cast treatment in children with upper brachial plexus palsy,” Pediatric Rehabilitation, vol. 9, no. 2, pp. 165–170, 2006. View at Publisher · View at Google Scholar · View at PubMed
  102. C. DeMatteo, J. R. Bain, V. Galea, and D. Gjertsen, “Botulinum toxin as an adjunct to motor learning therapy and surgery for obstetrical brachial plexus injury,” Developmental Medicine and Child Neurology, vol. 48, no. 4, pp. 245–252, 2006. View at Publisher · View at Google Scholar · View at PubMed
  103. A. E. Price, P. DiTaranto, I. Yaylali, M. A. Tidwell, and J. A. I. Grossman, “Botulinum toxin type A as an adjunct to the surgical treatment of the medial rotation deformity of the shoulder in birth injuries of the brachial plexus,” Journal of Bone and Joint Surgery. Series B, vol. 89, no. 3, pp. 327–329, 2007. View at Publisher · View at Google Scholar · View at PubMed
  104. D. Gobets, H. Beckerman, V. D. Groot, M. H. Van Doorn-Loogman, and J. G. Becher, “Indications and effects of botulinum toxin A for obstetric brachial plexus injury: a systematic literature review,” Developmental Medicine and Child Neurology, vol. 52, no. 6, pp. 517–528, 2010. View at Publisher · View at Google Scholar · View at PubMed
  105. A. Lipp, T. Trottenberg, T. Schink, A. Kupsch, and G. Arnold, “A randomized trial of botulinum toxin A for treatment of drooling,” Neurology, vol. 61, no. 9, pp. 1279–1281, 2003. View at Google Scholar
  106. G. Lagalla, M. Millevolte, M. Capecci, L. Provinciali, and M. G. Ceravolo, “Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling,” Journal of Neurology, vol. 256, no. 4, pp. 563–567, 2009. View at Publisher · View at Google Scholar · View at PubMed
  107. J. Costa, M. L. Rocha, J. Ferreira, T. Evangelista, M. Coelho, and M. de Carvalho, “Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis,” Journal of Neurology, vol. 255, no. 4, pp. 545–550, 2008. View at Publisher · View at Google Scholar · View at PubMed
  108. C. E. Jackson, G. Gronseth, J. Rosenfeld et al., “Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients,” Muscle and Nerve, vol. 39, no. 2, pp. 137–143, 2009. View at Publisher · View at Google Scholar · View at PubMed
  109. M. Porta, M. Gamba, G. Bertacchi, and P. Vaj, “Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders,” Journal of Neurology Neurosurgery and Psychiatry, vol. 70, no. 4, pp. 538–540, 2001. View at Publisher · View at Google Scholar
  110. G. Lagalla, M. Millevolte, M. Capecci, L. Provinciali, and M. G. Ceravolo, “Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study,” Movement Disorders, vol. 21, no. 5, pp. 704–707, 2006. View at Publisher · View at Google Scholar · View at PubMed
  111. A. C. Nóbrega, B. Rodrigues, A. C. Torres, A. Enzo, and A. Melo, “Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?” Journal of the Neurological Sciences, vol. 253, no. 1-2, pp. 85–87, 2007. View at Publisher · View at Google Scholar · View at PubMed
  112. F. Mancini, R. R. Zangaglia, S. Cristina et al., “Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling Parkinsonism,” Movement Disorders, vol. 18, no. 6, pp. 685–688, 2003. View at Publisher · View at Google Scholar · View at PubMed
  113. W. G. Ondo, C. Hunter, and W. Moore, “A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease,” Neurology, vol. 62, no. 1, pp. 37–40, 2004. View at Google Scholar
  114. S. J. Bachrach, R. S. Walter, and K. Trzcinski, “Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy,” Clinical Pediatrics, vol. 37, no. 8, pp. 485–490, 1998. View at Google Scholar
  115. S. M. Reid, B. R. Johnstone, C. Westbury, B. Rawicki, and D. S. Reddihough, “Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders,” Developmental Medicine and Child Neurology, vol. 50, no. 2, pp. 123–128, 2008. View at Google Scholar
  116. A. H. Alrefai, S. K. Aburahma, and Y. S. Khader, “Treatment of sialorrhea in children with Cerebral Palsy: a double-blind placebo controlled trial,” Clinical Neurology and Neurosurgery, vol. 111, no. 1, pp. 79–82, 2009. View at Publisher · View at Google Scholar · View at PubMed
  117. J. E. Bothwell, K. Clarke, J. M. Dooley et al., “Botulinum toxin A as a treatment for excessive drooling in children,” Pediatric Neurology, vol. 27, no. 1, pp. 18–22, 2002. View at Publisher · View at Google Scholar
  118. M. Ellies, S. Rohrbach-Volland, C. Arglebe, B. Wilken, R. Laskawi, and F. Hanefeld, “Successful management of drooling with botulinum toxin A in neurologically disabled children,” Neuropediatrics, vol. 33, no. 6, pp. 327–330, 2002. View at Publisher · View at Google Scholar · View at PubMed
  119. Y. C. Lin, J. Y. Shieh, M. L. Cheng, and P. Y. Yang, “Botulinum toxin type a for control of drooling in Asian patients with cerebral palsy,” Neurology, vol. 70, no. 4, pp. 316–318, 2008. View at Publisher · View at Google Scholar · View at PubMed
  120. D. Dressler, F. Adib Saberi, and R. Benecke, “Botulinum toxin type B for treatment of axillar hyperhidrosis,” Journal of Neurology, vol. 249, no. 12, pp. 1729–1732, 2002. View at Publisher · View at Google Scholar · View at PubMed
  121. A. M. Lang, “A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: a retrospective, open-label chart review,” Clinical Therapeutics, vol. 25, no. 8, pp. 2268–2278, 2003. View at Publisher · View at Google Scholar
  122. R. Tintner, R. Gross, U. F. Winzer, K. A. Smalky, and J. Jankovic, “Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial,” Neurology, vol. 65, no. 5, pp. 765–767, 2005. View at Publisher · View at Google Scholar · View at PubMed
  123. J. C. Arezzo, “NeuroBloc/Myobloc: unique features and findings,” Toxicon, vol. 54, no. 5, pp. 690–696, 2009. View at Publisher · View at Google Scholar · View at PubMed
  124. M. Basciani, D. Intiso, R. P. Cioffi, and P. Tonali, “Preoperative treatment with botulinum a toxin in patients with cervical disk herniation secondary to dystonic cerebral palsy,” Neurological Sciences, vol. 21, no. 1, p. 63, 2000. View at Publisher · View at Google Scholar
  125. D. Intiso, M. Basciani, F. Di Rienzo, M. Tolfa, G. Grimaldi, and P. Fiore, “Botulinum toxin type A in the healing of ulcer following oro-mandibular dyskinesia in a patient in a vegetative state,” Journal of Rehabilitation Medicine, vol. 40, no. 4, pp. 315–316, 2008. View at Publisher · View at Google Scholar · View at PubMed
  126. D. Intiso and M. Basciani, “Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury,” Journal of Rehabilitation Medicine, vol. 41, no. 13, pp. 1100–1102, 2009. View at Publisher · View at Google Scholar · View at PubMed
  127. C. C. Turkel, B. Bowen, J. Liu, and M. F. Brin, “Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity,” Archives of Physical Medicine and Rehabilitation, vol. 87, no. 6, pp. 786–792, 2006. View at Publisher · View at Google Scholar · View at PubMed
  128. A. W. Willis, B. Crowner, J. E. Brunstrom, A. Kissel, and B. A. Racette, “High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy,” Developmental Medicine and Child Neurology, vol. 49, no. 11, pp. 818–822, 2007. View at Publisher · View at Google Scholar · View at PubMed
  129. C. Albavera-Hernández, J. M. Rodríguez, and A. J. Idrovo, “Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials,” Clinical Rehabilitation, vol. 23, no. 5, pp. 394–407, 2009. View at Publisher · View at Google Scholar · View at PubMed
  130. K. Howell, P. Selber, H. K. Graham, and D. Reddihough, “Botulinum neurotoxin A: an unusual systemic effect,” Journal of Paediatrics and Child Health, vol. 43, no. 6, pp. 499–501, 2007. View at Publisher · View at Google Scholar · View at PubMed
  131. B. E. Crowner, D. Torres-Russotto, A. R. Carter, and B. A. Racette, “Systemic weakness after therapeutic injections of botulinum toxin A: a case series and review of the literature,” Clinical Neuropharmacology, vol. 33, no. 5, pp. 243–247, 2010. View at Publisher · View at Google Scholar · View at PubMed
  132. E. Varghese-Kroll and E. P. Elovic, “Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of post-stroke spasticity,” American Journal of Physical Medicine and Rehabilitation, pp. 495–499, 2009. View at Google Scholar
  133. M. P. Barnes, D. Best, L. Kidd et al., “The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A—initial experiences,” European Journal of Neurology, vol. 12, no. 12, pp. 947–955, 2005. View at Publisher · View at Google Scholar · View at PubMed
  134. S. A. Factor, E. S. Molho, S. Evans, and P. J. Feustel, “Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia,” Movement Disorders, vol. 20, no. 9, pp. 1152–1160, 2005. View at Publisher · View at Google Scholar · View at PubMed
  135. J. Herrmann, K. Geth, V. Mall et al., “Clinical impact of antibody formation to botulinum toxin A in children,” Annals of Neurology, vol. 55, no. 5, pp. 732–735, 2004. View at Publisher · View at Google Scholar · View at PubMed
  136. L. A. Koman, A. Brashear, S. Rosenfeld et al., “Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial,” Pediatrics, vol. 108, no. 5, pp. 1062–1071, 2001. View at Publisher · View at Google Scholar
  137. S. A. Yablon, A. Brashear, M. F. Gordon et al., “Formation of neutralizing antibodies in patients receiving botulinum toxin type a for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials,” Clinical Therapeutics, vol. 29, no. 4, pp. 683–690, 2007. View at Publisher · View at Google Scholar · View at PubMed
  138. S. Berweck, A. S. Schroeder, S. H. Lee, H. Bigalke, and F. Heinen, “Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands,” Developmental Medicine and Child Neurology, vol. 49, no. 1, pp. 62–64, 2007. View at Publisher · View at Google Scholar
  139. C. Cordivari, V. P. Misra, A. Vincent, S. Catania, K. P. Bhatia, and A. J. Lees, “Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test,” Movement Disorders, vol. 21, no. 10, pp. 1737–1741, 2006. View at Publisher · View at Google Scholar · View at PubMed